Omega Therapeutics, Inc. (OMGA)

NASDAQ: OMGA · IEX Real-Time Price · USD
2.15
-0.15 (-6.52%)
At close: Sep 29, 2023, 4:00 PM
2.24
+0.09 (4.19%)
After-hours: Sep 29, 2023, 7:40 PM EDT
-6.52%
Market Cap 118.55M
Revenue (ttm) 2.61M
Net Income (ttm) -111.59M
Shares Out 55.14M
EPS (ttm) -2.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 85,254
Open 2.32
Previous Close 2.30
Day's Range 2.12 - 2.41
52-Week Range 2.11 - 11.98
Beta 0.66
Analysts Strong Buy
Price Target 11.00 (+411.63%)
Earnings Date Nov 7, 2023

About OMGA

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, an... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 116
Stock Exchange NASDAQ
Ticker Symbol OMGA
Full Company Profile

Financial Performance

In 2022, OMGA's revenue was $2.07 million, an increase of 1339.58% compared to the previous year's $144,000. Losses were -$102.70 million, 50.4% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for OMGA stock is "Strong Buy." The 12-month stock price forecast is $11.0, which is an increase of 411.63% from the latest price.

Price Target
$11.0
(411.63% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

All 8 patients treated with OTX-2002 in initial two cohorts achieved highly specific on-target genomic engagement, intended epigenetic state change and robust downregulation in expression of c-MYC , a...

4 days ago - GlobeNewsWire

Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...

4 days ago - GlobeNewsWire

Omega Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...

8 days ago - GlobeNewsWire

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Developmen...

Other symbols: DNLIFHTXMCRBMRNASANA
19 days ago - PRNewsWire

Omega Therapeutics Announces Updates to its Board of Directors

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

4 weeks ago - GlobeNewsWire

Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

2 months ago - GlobeNewsWire

Omega Therapeutics Appoints Chris Schade to its Board of Directors

Accomplished Industry Veteran Brings Deep Strategic and Operational Expertise Accomplished Industry Veteran Brings Deep Strategic and Operational Expertise

2 months ago - GlobeNewsWire

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

Empress's Chemilogics™ product platform creates small molecule drugs quickly and cost-effectively The company emerges after two years of platform development with an initial commitment of $50 million ...

Other symbols: DNLIFHTXMCRBMRNASANA
3 months ago - PRNewsWire

Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors

REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers t...

4 months ago - GlobeNewsWire

Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting

CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable e...

4 months ago - GlobeNewsWire

Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable e...

5 months ago - GlobeNewsWire

Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...

5 months ago - GlobeNewsWire

Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...

6 months ago - GlobeNewsWire

Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...

7 months ago - GlobeNewsWire

Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock

CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

7 months ago - GlobeNewsWire

Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

9 months ago - GlobeNewsWire

KSQ Appoints Mahesh Karande to its Board of Directors

LEXINGTON, Mass.--(BUSINESS WIRE)--KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery C...

10 months ago - Business Wire

Omega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

CAMBRIDGE, Mass. , Nov. 17, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeu...

11 months ago - PRNewsWire

Omega Therapeutics Named One of BioSpace's 2023 Best Places to Work

CAMBRIDGE, Mass. , Nov. 15, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeu...

11 months ago - PRNewsWire

Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

First Patient Dosed in Phase 1/2 MYCHELANGELO™  I Trial of OTX-2002 OTX-2002 Granted Orphan Drug Designation by U.S. FDA for the Treatment of Hepatocellular Carcinoma OTX-2101 for MYC-Driven Non-Small...

11 months ago - PRNewsWire

Omega Therapeutics to Participate in the Jefferies London Healthcare Conference

CAMBRIDGE, Mass. , Nov. 3, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeut...

11 months ago - PRNewsWire

Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma

Phase 1/2 MYCHELANGELO™ I Clinical Trial Underway to Evaluate Safety, Tolerability and Preliminary Antitumor Activity of OTX-2002 CAMBRIDGE, Mass. , Nov. 2, 2022 /PRNewswire/ -- Omega Therapeutics, In...

11 months ago - PRNewsWire

Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene

OTX-2002 is the First-Ever Epigenomic Controller in a New Class of Programmable mRNA Therapeutics to be Administered to Patients CAMBRIDGE, Mass. , Oct. 27, 2022 /PRNewswire/ -- Omega Therapeutics, In...

1 year ago - PRNewsWire

Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting MYC-Driven Non-Small Cell Lung Cancer

OTX-2101 is the Second Development Candidate Arising from the Company's Pioneering OMEGA Epigenomic Programming™ Platform CAMBRIDGE, Mass. , Oct. 12, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nas...

1 year ago - PRNewsWire

Omega Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

CAMBRIDGE, Mass. , Sept. 6, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeu...

1 year ago - PRNewsWire